Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia

How to Cite

OrthoEvidence. Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia. ACE Report. 2019;8(4):17. Available from: https://myorthoevidene.com/AceReport/Report/11001

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:N/A

Fracture Prevention with Zoledronate in Older Women with Osteopenia

N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082

Contributing Authors: IR Reid S Wong MJ Bolland GD Gamble B Mihov AM Horne A Stewart E Garratt KR Wiessing S Bastin

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

2000 postmenopausal women with osteopenia were randomized to treatment with infusion of either zoledronate 5mg or placebo every 18 months for 6 years. Participants were assessed for incidence of fractures, prespecified adverse events including mortality, vascular events, cancer, and osteonecrosis of the jaw, and bone mineral density after 6 years. Results demonstrated significantly lower incidence...